Literature DB >> 11085507

Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison.

H Gao1, E F Yamasaki, K K Chan, L L Shen, R M Snapka.   

Abstract

Chloroquinoxaline sulfonamide (chlorosulfaquinoxaline, CQS, NSC 339004) is active against murine and human solid tumors. On the basis of its structural similarity to the topoisomerase IIbeta-specific drug XK469, CQS was tested and found to be both a topoisomerase-IIalpha and a topoisomerase-IIbeta poison. Topoisomerase II poisoning by CQS is essentially undetectable in assays using the common protein denaturant SDS, but easily detectable with strong chaotropic protein denaturants. The finding that detection of topoisomerase poisoning can be so dependent on the protein denaturant used in the assay has implications for drug discovery efforts and for our understanding of topoisomerase poisons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085507

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Nicotine mediates hypochlorous acid-induced nuclear protein damage in mammalian cells.

Authors:  Samir A Salama; Hany H Arab; Hany A Omar; Ibrahim A Maghrabi; Robert M Snapka
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

2.  Synthesis, structure, and biological activity of novel heterocyclic sulfonyl-carboximidamides.

Authors:  Katarzyna Gobis; Henryk Foks; Jarosław Sławiński; Artur Sikorski; Damian Trzybiński; Ewa Augustynowicz-Kopeć; Agnieszka Napiórkowska; Krzysztof Bojanowski
Journal:  Monatsh Chem       Date:  2013-01-25       Impact factor: 1.451

3.  A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC).

Authors:  Tanios S Bekaii-Saab; Amir Mortazavi; Lee G Hicks; Mark Zalupski; Robert J Pelley; Kenneth K Chan; Eric H Kraut
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

4.  Synthesis of Morpholine-, Piperidine-, and N-Substituted Piperazine-Coupled 2-(Benzimidazol-2-yl)-3-arylquinoxalines as Novel Potent Antitumor Agents.

Authors:  Vakhid A Mamedov; Nataliya A Zhukova; Alexandra D Voloshina; Victor V Syakaev; Tat'yana N Beschastnova; Anna P Lyubina; Syumbelya K Amerhanova; Aida I Samigullina; Aidar T Gubaidullin; Daina N Buzyurova; Il Dar Kh Rizvanov; Oleg G Sinyashin
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-01

Review 5.  Recent advances in the transition-metal-free synthesis of quinoxalines.

Authors:  Biplob Borah; L Raju Chowhan
Journal:  RSC Adv       Date:  2021-11-19       Impact factor: 4.036

6.  Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents.

Authors:  Eman A Ahmed; Mamdouh F A Mohamed; Omran A Omran
Journal:  RSC Adv       Date:  2022-09-05       Impact factor: 4.036

7.  Repair of DNA strand breaks in a minichromosome in vivo: kinetics, modeling, and effects of inhibitors.

Authors:  Slawomir Kumala; Krzysztof Fujarewicz; Dheekollu Jayaraju; Joanna Rzeszowska-Wolny; Ronald Hancock
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 8.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

9.  Synthesis and Antimicrobial Activity of Some New Substituted Quinoxalines.

Authors:  Mohamed A El-Atawy; Ezzat A Hamed; Mahjoba Alhadi; Alaa Z Omar
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.